The present study provides convincing data to establish an enhanced anti-tumor effect of paclitaxel caused by combining flubendazole via HIF1α/PI3K/AKT signaling pathways for BC therapy, which contributes to reducing the clinical dose of paclitaxel, thus diminishing baneful adverse reactions. Here, HIF1A is linked to breast cancer.